» Articles » PMID: 22895158

Dry Eye Medication Use and Expenditures: Data from the Medical Expenditure Panel Survey 2001 to 2006

Overview
Journal Cornea
Specialty Ophthalmology
Date 2012 Aug 17
PMID 22895158
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To study dry eye medication use and expenditures from 2001 to 2006 using a nationally representative sample of US adults.

Methods: This study retrospectively analyzed dry eye medication use and expenditures of participants of the 2001 to 2006 Medical Expenditure Panel Survey, a nationally representative subsample of the National Health Interview Survey. After adjusting for survey design and for inflation using the 2009 inflation index, data from 147 unique participants aged 18 years or older using the prescription medications Restasis and Blephamide were analyzed. The main outcome measures were dry eye medication use and expenditures from 2001 to 2006.

Results: Dry eye medication use and expenditures increased between the years 2001 and 2006, with the mean expenditure per patient per year being $55 in 2001 to 2002 (n=29), $137 in 2003 to 2004 (n=32), and $299 in 2005 to 2006 (n=86). This finding was strongly driven by the introduction of topical cyclosporine emulsion 0.05% (Restasis; Allergan, Irvine, CA). In analysis pooled over all survey years, demographic factors associated with dry eye medication expenditures included gender (female: $244 vs. male: $122, P<0.0001), ethnicity (non-Hispanic: $228 vs. Hispanic: $106, P<0.0001), and education (greater than high school: $250 vs. less than high school: $100, P<0.0001).

Conclusions: We found a pattern of increasing dry eye medication use and expenditures from 2001 to 2006. Predictors of higher dry eye medication expenditures included female gender, non-Hispanic ethnicity, and greater than a high school education.

Citing Articles

Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease.

Valdes-Arias D, Locatelli E, Sepulveda-Beltran P, Mangwani-Mordani S, Navia J, Galor A Drugs. 2024; 84(5):549-563.

PMID: 38652355 PMC: 11189955. DOI: 10.1007/s40265-024-02031-6.


Anti-inflammatory and antioxidative effects of gallic acid on experimental dry eye: in vitro and in vivo studies.

Li K, Gong Q, Lu B, Huang K, Tong Y, Mutsvene T Eye Vis (Lond). 2023; 10(1):17.

PMID: 37122017 PMC: 10150500. DOI: 10.1186/s40662-023-00334-5.


Elevated Rheumatoid Factor Associates with Dry Eye in Patients with Common Autoimmune Diseases.

Zhao S, Xiao Y, Zhang S, Liu L, Chen K J Inflamm Res. 2022; 15:2789-2794.

PMID: 35535054 PMC: 9078869. DOI: 10.2147/JIR.S365326.


Estimated Annual Economic Burden of Dry Eye Disease Based on a Multi-Center Analysis in China: A Retrospective Study.

Yang W, Luo Y, Wu S, Niu X, Yan Y, Qiao C Front Med (Lausanne). 2021; 8:771352.

PMID: 34926513 PMC: 8673084. DOI: 10.3389/fmed.2021.771352.


Cost utility analysis of cryopreserved amniotic membrane versus topical cyclosporine for the treatment of moderate to severe dry eye syndrome.

Voigt J Cost Eff Resour Alloc. 2020; 18(1):56.

PMID: 33292325 PMC: 7709448. DOI: 10.1186/s12962-020-00252-6.


References
1.
Fiscella R, Lee J, Walt J, Killian T . Utilization characteristics of topical cycolsporine and punctal plugs in a managed care database. Am J Manag Care. 2008; 14(3 Suppl):S107-12. View

2.
Schaumberg D, Sullivan D, Dana M . Epidemiology of dry eye syndrome. Adv Exp Med Biol. 2003; 506(Pt B):989-98. DOI: 10.1007/978-1-4615-0717-8_140. View

3.
Uchino M, Schaumberg D, Dogru M, Uchino Y, Fukagawa K, Shimmura S . Prevalence of dry eye disease among Japanese visual display terminal users. Ophthalmology. 2008; 115(11):1982-8. DOI: 10.1016/j.ophtha.2008.06.022. View

4.
Schein O, Munoz B, Tielsch J, Bandeen-Roche K, West S . Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997; 124(6):723-8. DOI: 10.1016/s0002-9394(14)71688-5. View

5.
Bandeen-Roche K, Munoz B, Tielsch J, West S, Schein O . Self-reported assessment of dry eye in a population-based setting. Invest Ophthalmol Vis Sci. 1997; 38(12):2469-75. View